BriaCell Therapeutics Corp. Stock price Nasdaq
Equities
BCTX
CA1079301091
Biotechnology & Medical Research
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
2.86 USD | +7.12% | +25.44% | -51.11% |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 45.82M |
---|---|---|---|---|---|
Net income 2024 * | -13M | Net income 2025 * | -22M | EV / Sales 2024 * | - |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-3.63
x | P/E ratio 2025 * |
-2.73
x | Employees | 16 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 82.83% |
1 day | +7.12% | ||
1 week | +25.44% | ||
Current month | -17.34% | ||
1 month | -15.88% | ||
3 months | -47.71% | ||
6 months | -51.03% | ||
Current year | -51.11% |
Managers | Title | Age | Since |
---|---|---|---|
William Williams
CEO | Chief Executive Officer | 68 | 16-10-31 |
Gadi Levin
DFI | Director of Finance/CFO | 52 | 16-01-31 |
Chief Tech/Sci/R&D Officer | 53 | 21-04-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Martin Schmieg
BRD | Director/Board Member | 62 | 16-05-09 |
Marc Lustig
BRD | Director/Board Member | 51 | 21-08-30 |
Rebecca Taub
BRD | Director/Board Member | 71 | 18-03-06 |
Date | Price | Change | Volume |
---|---|---|---|
24-03-28 | 2.86 | +7.12% | 87,185 |
24-03-27 | 2.67 | +5.12% | 85,183 |
24-03-26 | 2.54 | -10.88% | 146,432 |
24-03-25 | 2.85 | +13.10% | 190,437 |
24-03-22 | 2.52 | +10.53% | 138,875 |
Delayed Quote Nasdaq, March 28, 2024 at 04:30 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+2.73% | 108B | |
+9.59% | 103B | |
+6.58% | 23.48B | |
-12.59% | 21.93B | |
-3.29% | 19.68B | |
-35.36% | 18.37B | |
-13.29% | 16.33B | |
+4.68% | 13.72B | |
+34.25% | 12.15B |
- Stock
- Equities
- Stock BriaCell Therapeutics Corp.
- Stock BriaCell Therapeutics Corp. - Nasdaq